Moberg licenses OTC Nalox drug to Meda
Moberg Derma has given marketing license for its over-the-counter (OTC) Nalox to Meda as a treatment for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
The new deal covers several major European countries, such as Germany, France, the UK, Spain, Austria, the Netherlands and Belgium.
Under the deal, Meda is responsible to pay a sum of SEK 32m, with SEK13m when signing the contract and the remaining SEK19m in future milestone payments to Moberg.
Moberg CEO Peter Wolpert said this agreement is a key step in the global launch of Nalox.